Supernus Pharmaceuticals has reported positive results from a Phase IIa trial to evaluate SPN-812 as a treatment for attention deficit hyperactivity disorder (ADHD) in adults.

The study demonstrated that drug met primary endpoints of safety and tolerability, and that there was statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores.

The randomised, double-blind, placebo-controlled trial evaluated 53 adults with a current diagnosis of ADHD.

SPN-812 is a selective norepinephrine reuptake inhibitor, which, according to Supernus, could be more effective and have a better side effect profile than other non-stimulant treatments for ADHD due to its different pharmacological profile.